Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ikena Oncology (IKNA)
NASDAQ:IKNA
Holding IKNA?
Track your performance easily
IKNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.02 - $4.95
Previous Close$1.66
Volume37.44K
Average Volume (3M)154.58K
Market Cap
$80.11M
Enterprise Value-$56.22M
Total Cash (Recent Filing)$145.42M
Total Debt (Recent Filing)$9.09M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Nov 06, 2024EPS Estimate
-$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding48,258,111
10 Day Avg. Volume36,665
30 Day Avg. Volume154,576
Standard Deviation0.25
R-Squared0.00880
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.56
Price to Sales (P/S)43.70
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-30.49
Enterprise Value/Gross Profit-6.14
Enterprise Value/Ebitda1.12
Forecast
1Y Price Target
$3.00Price Target Upside75.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Ikena Oncology News
PremiumCompany Announcements
Ikena Oncology Promotes Jotin Marango to Chief Operating Officer
PremiumCompany Announcements
Ikena Oncology Announces Strategic Restructuring and Exploration Options
Bulls Say, Bears Say
Bulls Say
Drug Resistance StrategyIK-595 represents one of the most advanced strategies to combat drug resistance stemming from the MAPK pathway.
Innovation And LeadershipIkena remains at the forefront of development of what could be a best-in-class molecular glue toward RAF/MEK.
Therapeutic DevelopmentFocusing on the development of IK-595 as a mono and combination therapy across RAS and RAF altered cancers is a net positive.
Bears Say
Efficacy ConcernsUpon release of the data, IMRX stock fell -53% stemming from a lack of efficacy at the RP2D dose level, bringing into question IMM-1-104’s mechanistic rationale.
Expert SkepticismOur KOL is not convinced that deep cyclic inhibition is real, noting that despite a clean safety profile, the need to sacrifice efficacy raises concerns.
Safety Vs. Efficacy Trade-offWhile IMM-1-104 was designed to have a short plasma half-life, the strategy's improvement on safety seems thus far to come at the cost of efficacy.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IKNA FAQ
What was Ikena Oncology’s price range in the past 12 months?
Ikena Oncology lowest stock price was $1.02 and its highest was $4.95 in the past 12 months.
What is Ikena Oncology’s market cap?
Currently, no data Available
When is Ikena Oncology’s upcoming earnings report date?
Ikena Oncology’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Ikena Oncology’s earnings last quarter?
Ikena Oncology released its earnings results on Aug 08, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.346 by $0.066.
Is Ikena Oncology overvalued?
According to Wall Street analysts Ikena Oncology’s price is currently Undervalued.
Does Ikena Oncology pay dividends?
Ikena Oncology does not currently pay dividends.
What is Ikena Oncology’s EPS estimate?
Ikena Oncology’s EPS estimate is -$0.26.
How many shares outstanding does Ikena Oncology have?
Ikena Oncology has 48,258,110 shares outstanding.
What happened to Ikena Oncology’s price movement after its last earnings report?
Ikena Oncology reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.346. Following the earnings report the stock price went down -0.613%.
Which hedge fund is a major shareholder of Ikena Oncology?
Among the largest hedge funds holding Ikena Oncology’s share is Omega Fund Management, LLC. It holds Ikena Oncology’s shares valued at 4M.
---
Ikena Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (75.44% Upside)
$3.00 (75.44% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-61.75%
12-Months-Change
Fundamentals
Return on Equity
-44.54%
Trailing 12-Months
Asset Growth
-8.31%
Trailing 12-Months
Company Description
Ikena Oncology
Ikena Oncology Inc is an oncology company. It is focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. The company is advancing five clinical, preclinical and discovery programs: IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme Kynase; discovery-stage molecules targeting the Hippo signaling pathway; and a discovery-stage program against an undisclosed target.
---
IKNA Stock 12 Month Forecast
Average Price Target
$3.00
▲(75.44% Upside)
Technical Analysis
Best Analysts Covering IKNA
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
-12.71%
reiterated a buy rating last month
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of -12.71% per trade.
---